Overview
Safety information for 5-Amino-1MQ depends on how extensively it has been studied in humans, how it is manufactured, and in what context it is used. Many catalog peptides have more preclinical than clinical safety data.
Common safety themes
For peptides in general, discussions of side effects often include:
- Local reactions at injection sites.
- Systemic symptoms such as headache, fatigue, or gastrointestinal upset.
- Uncertainties related to long-term exposure, interactions, and product quality.
Context and caveats
Absence of large, well-controlled human studies means that true risk profiles for many peptides remain incompletely defined. Regulatory status, manufacturing controls, and supervision by qualified clinicians are central to interpreting any safety conversation about 5-Amino-1MQ.
Sport & Anti-Doping Warning
5-amino-1MQ is a small-molecule NNMT inhibitor marketed in some wellness and physique circles; as an unapproved drug, it falls into the general S0 category of non-approved substances under the World Anti-Doping Code.
- >Background on 5-amino-1MQ as an experimental metabolic agent
- >WADA guidance that non-approved drugs are prohibited under S0
Even when not named explicitly on the Prohibited List, experimental metabolic drugs like 5-amino-1MQ are captured by the S0 'non-approved substance' rule.